Baker Bros. Advisors
Baker Bros. Advisors reported 83 stocks worth $19.9B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are INCY (17.5%), ONC (12.6%) and RVMD (10.8%). Compared with Q1 2026, the fund opened new positions in FTH, CYTK and NTLA, added to RVMD, INSM and ABCL, trimmed SMMT, IMVT and ROIV and sold out of ABVX, CELC and SYRE.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  INCY Incyte Corp | $3.5B | 17.5% | 30.8M | No change | 8 of 8 | |
| 2 |  ONC Beone Medicines Ltd | $2.5B | 12.6% | 8.8M | No change | 8 of 8 | |
| 3 |  RVMD Revolution Medicines Inc | $2.1B | 10.8% | 11.4M | +1.9M (+20%) | 8 of 8 | |
| 4 |  MDGL Madrigal Pharmaceuticals Inc | $1.2B | 5.8% | 2.1M | No change | 8 of 8 | |
| 5 |  ACAD Acadia Pharmaceuticals Inc | $1.1B | 5.5% | 42.9M | No change | 8 of 8 | |
| 6 |  KYMR Kymera Therapeutics Inc | $993M | 5.0% | 8.7M | No change | 8 of 8 | |
| 7 |  INSM Insmed Inc | $938M | 4.7% | 8.8M | +1.4M (+19%) | 8 of 8 | |
| 8 |  CELC Celcuity Inc | $828M | 4.2% | 7.9M | No change | 8 of 8 | |
| 9 |  KOD Kodiak Sciences Inc | $776M | 3.9% | 19.9M | No change | 8 of 8 | |
| 10 |  RYTM Rhythm Pharmaceuticals Inc | $622M | 3.1% | 5.6M | No change | 8 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 ABVX Abivax SA | $97.5M | 876K |
CELC Celcuity Inc | $74.9M | 30.8M |
 SYRE Spyre Therapeutics Inc | $50.4M | 1M |
CENTESSA PHARMACEUTICALS PLC | $26.6M | 671K |
 IMCR Immunocore Hldgs PLC | $22.1M | 734K |
🔒 Free account: see all 9.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Baker Bros. Advisors 13F FAQ
What does Baker Bros. Advisors own?
Baker Bros. Advisors reported 83 stocks worth $19.9B in its 13F filing for Q2 2026, filed Aug 14, 2026. The table above lists every position in the filing (the top 10 without an account).
What did Baker Bros. Advisors buy and sell in Q2 2026?
Compared with Q1 2026: 8 new positions, 11 added to, 7 trimmed and 9 sold out. New positions include FTH, CYTK and NTLA. It sold all of ABVX, CELC and SYRE.
When will Baker Bros. Advisors file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Baker Bros. Advisors's portfolio worth?
The Q2 2026 filing reports $19.9B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.